Study of the safety, immunogenicity and efficacy of attenuated and killed Leishmania (Leishmania) major vaccines in a rhesus monkey (Macaca mulatta) model of the human disease

Memorias do Instituto Oswaldo Cruz

Volumn 97, Issue 7, 2002, Pages 1041-1048

  Amaral, V F ^a   Teva, A ^a   Oliveira Neto, M P ^c   Silva, A J ^a   Pereira, M S ^a   Cupolillo, E ^a   Porrozzi, R ^a   Coutinho, S G ^a   Pirmez, C ^b   Beverley, S M ^d   Grimaldi Jr , G ^a  

^a Departamento de Imunologia   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c Ctro Pesquisa Hosp Evandro C   (Brazil)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Attenuated and killed promastigotes; Bacillus Calmete Guerin (BCG); Leishmania (L.) major; Rhesus macaques (Macaca mulatta); Vaccination

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; INACTIVATED VACCINE; LIVE VACCINE; PARASITE ANTIGEN; PROTOZOAL VACCINE;

ANIMAL; ARTICLE; BIOSYNTHESIS; DELAYED HYPERSENSITIVITY; DISEASE MODEL; IMMUNOLOGY; LEISHMANIA MAJOR; MACACA; SKIN LEISHMANIASIS;

ANIMALS; ANTIGENS, PROTOZOAN; BCG VACCINE; DISEASE MODELS, ANIMAL; HYPERSENSITIVITY, DELAYED; INTERFERON TYPE II; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; MACACA MULATTA; PROTOZOAN VACCINES; VACCINES, ATTENUATED; VACCINES, INACTIVATED;

EID: 0036783228     PISSN: 00740276     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0074-02762002000700019     Document Type: Article

References (32)

1. Amaral VF, Ransatto VAO, Conceiçào-Silva F, Molinaro E, Ferreira V, Coutinho SG, McMahon-Pratt D, Grimaldi Jr G 1996. The Asian Rhesus macaques (Macaca mulatta) as an experimental model for study of cutaneous leishmaniasis. Exp Parasitol 82: 34-44.
2. Amaral VF, Teva A, Porrozzi R, Silva AJ, Pereira MS, Oliveira-Neto MP, Grimaldi Jr G 2001. Leishmania (Leishmania) mojor-infected rhesus macaques (Macaca mulatta) develop varying levels of resistance against homologous reinfections. Mem Inst Oswaldo Cruz 96: 795-804.
3. Antunes CM, Mayrink W, Magalhaes PA, Costa CA, Melo MN, Dias M, Michalick MS, Williams P, Lima AO, Vieira JB, Schettini APM 1986. Controlled field trials of a vaccine against New World cutaneous leishmaniasis. Int J Epidemiol 15: 572-580.
4. Armijos RX, Weigel MM, Aviles H, Maldonado R, Racines J 1998. Field trial of a vaccine against New World cutaneous leishmaniasis in an at-risk child population: safety, immunogenicity, and efficacy during the first 12 months of follow-up. J Infect Dis 177: 1352-1357.
5. Campos-Neto A, Porrozzi R, Greeson K, Coler RN, Webb JR, Seiky YA, Reed SG, Grimaldi Jr G 2001. Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease, Infect Immun 69: 4103-4108.
6. Chaparas SD, Good RC, Janicki BW 1975.Tuberculin-induced lymphocyte transformation and skin reactivity in monkeys vaccinated or not vaccinated with Bacille Calmette-Guérin, then challenged with virulent Mycobacterium tuberculosis. Am Rev Resp Dis 112: 43-47.
7. Dennis VA, Lujan R, Chapman WL Jr, Hanson WL 1986. Leishmania donovani: cellular and humoral immune responses after primary and challenge infections in squirrel monkeys, Saimiri sciureus. Exp Parasitol 61: 319-334.
8. Dube A. Sharma P, Srivastava JK, Misra A, Naik S, Katiyar JC 1998. Vaccination of langur monkeys (Presbytis entellus) against Leishmania donovani with autoclaved L. major plus BCG. Parasitology 116: 219-221.
9. Dye C 1996. The logic of visceral leishmaniasis control. Am J Trop Med Hyg 55: 125-130.
10. Gicheru MM, Olobo JO, Anjili CO, Orago AS, Modabber F, Scott P 2001. Vervet monkeys vaccinated with killed Leishmania major parasites and interleukin-12 develop a type 1 immune response but are not protected against challenge infection. Infect Immun 69: 245-251.
11. Green MS, Kark J D, Witzum E, Greenblat CL, Spira DT 1983. Frozen stored L. tropica vaccine: the effect of dose, route for administration and storage on the evolution of clinical lesion. Two field trials in the Israel defense forces. Trans R Soc Trop Med Hyg 77: 152-159.
12. Grimaldi Jr G 1995. Meeting on vaccine studies towards the control of leishmaniasis. Mem Inst Oswaldo Cruz 90: 553-556.
13. Grimaldi Jr G, Tesh RB 1993. Leishmaniasis of the New World: current concepts and implications for future research. Clin Microb Rev 6: 230-250.
14. Grimaldi Jr G, Momen H, Naiff RD, McMahon-Pratt D, Barrett TV 1991. Characterization and classification of leishmanial parasites from humans, wild animals, and sand flies in the Amazon region of Brazil. Am J Trop Med Hyg 44: 645-661.
15. Gueiros-Filho FJ, Beverley SM 1996. Selection against Dihydrofolate Reductase-Thymidylate Synthase (DHFR-TS) as a probe of genetic alterations in Leishmania. Molec Cell Biol 16: 5655-5663.
16. Guirges SY 1971. Natural and experimental re-infection of man with Oriental sore. Ann Trop Med Parasitol 65: 197-205.
17. Gurunathan S, Prussin C, Sacks DL, Seder RA 1998. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection. Nat Med 4: 1409-1415.
18. Kemp M, Hey AS, Kurtzhals JA, Christensen CB 1994. Dichotomy of the human T cell response to Leishmania antigens. I. Thl-like activity response to Leishmania major promastigote antigens in individuals recovered from cutaneous leishmaniasis. Clin Exp Immunol 96: 410-415.
19. Kenney RT, Sacks DL, Sypek JP, Vilela L, Gam AA, Evans-Davis K 1999. Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis. J Immunol 163: 4481-4488.
20. Liew FY, Hale C, Howard JG 1985. Prophylactic immunization against experimental leishmaniasis. IV. Subcutaneous immunization prevents the induction of protective immunity against fatal Leishmania major infection. J Immunol 135: 2095-2101.
21. Mayrink W, da Costa CA, Magalhàes PA, Melo MN, Dias M, Oliveira Lima A, Michalick MS, Williams P 1979. A field trial of a vaccine against American dermal leishmaniasis. Trans R Soc Trop Med Hyg 73: 385-387.
22. McGurn M, Boon T, Louis JA. Titus RG 1990. Leishmania major: nature of immunity induced by immunization with a mutagenized avirulent clone of the parasite in mice. Exp Parasitol 71: 81-89.
23. Menon JN, Bretscher PA 1996. Characterization of the immunological memory state generated in mice susceptible to Leishmania major following exposure to low doses of L. major and resulting in resistance to a normally pathogenic challenge. Eur J Immunol 26: 243-249.
24. Momeni AZ, Jalayer T, Emamjomeh M, Khamesipour A, Zicker F, Ghassemi RL, Dowlati Y, Sharifi I, Aminjavaheri M, Shafiei A, Alimohammadian MH, Hashemi-Fesharki R, Nasseri K, Godal T, Smith PG, Modabber F 1999. A randomised, double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran. Vaccine 17: 466-472.
25. Naggan L, Gunders AE, Michaeli D 1972. Follow-up study of a vaccination programme against cutaneous leishmaniasis. II. Vaccination with a recently isolated strain of L. tropica from Jericho. Trans R Soc Trop Med Hyg 66: 239-243.
26. Olobo JO, Reid GD, Githure JI, Anjili CO 1992. IFN-gamma and delayed-type hypersensitivity are associated with cutaneous lcishmaniasis in vervet monkeys following secondary rechallenge with Leishmania major. Scand J Immunol (Suppl.) 11: 48-52.
27. Pirmez C, Trajano V, Oliveira-Neto MP, da-Cruz AM, Gonçalves-da-Costa SC, Catanho M, Degravc W, Fernandes O 1999. Use of PCR in diagnosis of human American tegumentary leishmaniasis in Rio de Janeiro, Brazil. J Clin Microbiol 37: 1819-1823.
28. Reed SG, Scott P 2000. Immunologic mechanisms in Leishmania. In MW Cunningham, RS Fujinami (eds), Effects of Microbes on the Immune System, Lippincott Williams, Wilkins, Philadelphia, p. 537-554.
29. Sarples CE, Shaw MA, Castes M, Convit J, Blackwell JM 1994. Immune response in healthy volunteers vaccinated with BCG plus killed leishmanial promastigotes: antibody responses to mycobacterial and leishmanial antigens. Vaccine 12: 1402-1412.
30. Sharifi I, FeKri AR, Aflatonian MR, Khamesipour A, Nadim A, Mousavi MR, Momeni AZ, Dowlati Y, Godal T, Zicker F, Smith PG, Modabber F 1998. Randomised vaccine trial of a single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet 351: 1540-1543.
31. Titus RG, Gueiros-Filho FJ, de Freitas LAR, Beverley SM 1995. Development of a safe live Leishmania vaccine line by gene replacement. Proc Natl Acad Sci USA 92: 10267-10271.
32. - Leishmania major knockout mutant cross-protects against Leishmania amazonensis. Mem Inst Oswaldo Cruz 94: 491-496.